Tissue-specific mTORC1 pulsatility governs the civilization‑survival trade‑off in aging

Hypothesis

Intermittent, tissue‑restricted inhibition of mTORC1 creates coordinated pulses of autophagy that preserve organismal 'civilization' functions (growth, reproduction, neuroendocrine signaling) while shifting peripheral tissues into a survival mode, thereby extending healthspan without the metabolic costs of global mTOR suppression.

Mechanistic rationale

• mTORC1 activity integrates amino acid, glucose, and energy signals to control anabolic programs [1].
• In neurons and pancreatic β‑cells, transient mTORC1 signaling sustains synaptic plasticity and insulin secretion, supporting organismal coordination [5].
• In liver, muscle, and adipose, low‑frequency mTORC1 inhibition triggers autophagic flux and mitophagy, reducing cellular damage [3].
• We propose that the nervous system monitors peripheral autophagic output via extracellular vesicles (EVs) carrying LC3‑II and mitophagy‑related miRNAs, feeding back to hypothalamic mTORC1 to adjust systemic nutrient allocation. This creates a feedback loop where central mTORC1 stays intermittently active ('civilization') while peripheral nodes oscillate into survival.

Testable predictions

1. Tissue‑specific rapamycin delivery (e.g., nanoparticle‑targeted to liver/muscle) given on an intermittent schedule (3 days on/4 days off) will improve glucose tolerance and grip strength in aged mice compared with continuous rapamycin or vehicle.
2. EV profiling from plasma will show elevated LC3‑II and mitophagy‑miR‑146a pulses synchronizing with hypothalamic p‑S6K (a readout of mTORC1 activity) only under the intermittent peripheral regimen.
3. Genetic disruption of hypothalamic mTORC1 (using CamKII‑Cre; Raptor^fl/fl) will abolish the healthspan benefits of peripheral intermittent rapamycin, confirming the central‑peripheral feedback requirement.
4. Conversely, forced constant mTORC1 activation in liver (AAV‑Rheb overexpression) will blunt autophagy induction and accelerate age‑related fibrosis despite peripheral rapamycin treatment.

Experimental outline (falsifiable)

• Use C57BL/6J mice aged 12 months. Four groups: (1) vehicle, (2) continuous rapamycin (14 ppm diet), (3) intermittent peripheral rapamycin (liver‑targeted nanoparticles, 3 days on/4 days off), (4) intermittent peripheral rapamycin + hypothalamic Raptor knockout.
• Measure lifespan, frailty index, glucose tolerance, grip strength, and histology at 6‑month intervals.
• Collect plasma EVs every two weeks; quantify LC3‑II by Western blot and miR‑146a by qPCR.
• Assess hypothalamic p‑S6K and peripheral p‑S6K levels via immunoblot.
• Statistical analysis: two‑way ANOVA with post‑hoc Tukey; survival curves compared by log‑rank test.

If intermittent peripheral rapamycin improves healthspan only when hypothalamic mTORC1 remains responsive, the hypothesis is supported. If benefits occur irrespective of central mTORC1 status, or if EV signals do not correlate with hypothalamic activity, the hypothesis is falsified.

Broader implication

This reframes the mTOR 'dial' not as a static setting but as a spatiotemporal oscillator where the organism balances collective functions (neuroendocrine, reproductive) with somatic maintenance through rhythmic, tissue‑specific mTORC1 activity. It suggests that optimal longevity interventions should synchronize rather than globally suppress mTOR signaling, preserving the civilizational aspects of complex life while fostering a survival state in the bulk of the soma.